- Conditions
- Irregular Sleep-Wake Rhythm Disorder
- Interventions
- Lemborexant 2.5 mg, Lemborexant 5 mg, Lemborexant 10 mg, Lemborexant 15 mg, Lemborexant-matched placebo
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 60 Years to 90 Years
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 37
- States / cities
- Little Rock, Arkansas • Rogers, Arkansas • Costa Mesa, California + 30 more
Source: ClinicalTrials.gov public record
Updated May 16, 2021 · Synced May 21, 2026, 7:18 PM EDT